Adakitug

N/A

Report date: 2024/11/28 16:25:46

Base Information

Drug NameAdakitug
Drug Alias NameHuMax-InflamHuMax-IL8HuMaxMDX-018BMS-986253
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-8 inhibitors
TargetsInterleukin-8
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursMyelodysplastic Syndromes +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMedarex IncGenmab A/SBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesBristol Myers Squibb Srlcompany
Inactive CompaniesColumbia UniversityNational Cancer Institute
Active IndicationsProstatic NeoplasmsCarcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of Head and Neck +[5] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursMyelodysplastic Syndromes +[5] 

Other Information

ATC CodeN/A
Related LinksN/A